Cargando…
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
BACKGROUND: The purpose of this study was to determine if eyes with diabetic macular edema (DME) unresponsive to ranibizumab or bevacizumab would benefit from conversion to aflibercept. METHODS: This study was conducted as a retrospective chart review of subjects with DME unresponsive to ranibizumab...
Autores principales: | Lim, Laurence S, Ng, Wei Yan, Mathur, Ranjana, Wong, Doric, Wong, Edmund YM, Yeo, Ian, Cheung, Chui Ming Gemmy, Lee, Shu Yen, Wong, Tien Yin, Papakostas, Thanos D, Kim, Leo A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577250/ https://www.ncbi.nlm.nih.gov/pubmed/26396494 http://dx.doi.org/10.2147/OPTH.S81523 |
Ejemplares similares
-
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021) -
Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi, Nasser G, et al.
Publicado: (2021) -
A Prospective Study of Treatment Patterns and 1-Year Outcome of Asian Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Cheung, Chui Ming Gemmy, et al.
Publicado: (2014) -
Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023) -
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Subgroup Analyses From the VIEW Trials
por: Wong, Tien Yin, et al.
Publicado: (2019)